Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 54,541 shares, a decrease of 56.8% from the October 15th total of 126,324 shares. Based on an average daily trading volume, of 67,646 shares, the days-to-cover ratio is presently 0.8 days. Approximately 6.5% of the shares of the stock are short sold.
Analyst Ratings Changes
MBRX has been the subject of several recent research reports. Wall Street Zen cut Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, October 15th. Finally, HC Wainwright reduced their target price on Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Moleculin Biotech has an average rating of “Hold” and an average target price of $60.00.
View Our Latest Analysis on Moleculin Biotech
Moleculin Biotech Trading Down 4.3%
MBRX traded down $0.31 during trading hours on Tuesday, hitting $6.83. 11,980 shares of the company’s stock were exchanged, compared to its average volume of 32,964. Moleculin Biotech has a 12-month low of $3.23 and a 12-month high of $227.05. The firm has a 50 day moving average of $9.80 and a 200 day moving average of $36.28. The firm has a market cap of $7.03 million, a P/E ratio of -0.05 and a beta of 2.11.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($9.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.87) by ($0.72). As a group, research analysts expect that Moleculin Biotech will post -47.40 EPS for the current fiscal year.
About Moleculin Biotech
Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.
See Also
- Five stocks we like better than Moleculin Biotech
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
